Article
Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study.
Clinical lung cancer - 1 Sept 2020
Moran Teresa, Taus Alvaro, Arriola Edurne, Aguado Carlos, Dómine Manuel, Rueda Ana Gómez, Calles Antonio, Cedrés Susana, Viñolas Nuria, Isla Dolores, Palmero Ramón, Sereno María, Diaz Victor, Juan Oscar, Marsé Raquel, Martorell Paloma Martín, Sánchez Torres José Miguel
Abstract excerpt
INTRODUCTION: Uncommon epidermal growth factor receptor (EGFR) mutations (u-EGFRm) are a heterogeneous group of molecular alterations and have also been reported as comutations with other EGFR mutations (complex mutations) in non-small-cell lung cancer (NSCLC). Afatinib has shown activity against some u-EGFRm, and we examined its efficacy in Spanish clinical practice. PATIENTS AND METHODS: Data of 67 patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.